Form 4: Collegium Pharma Exec Sells Shares After Option Exercise

Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, exercised stock options and subsequently sold 17,600 shares of common stock under a Rule 10b5-1 plan.

Summary

• Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, Inc., exercised options to acquire 17,600 shares of common stock at an exercise price of $15.9 per share.
• Following the option exercise, Dreyer sold a total of 17,600 shares of common stock in two separate transactions on the same day.
• The first sale involved 11,125 shares at a weighted average price of $47.8895 per share, with prices ranging from $47.212 to $48.20.
• The second sale involved 6,475 shares at a weighted average price of $48.6617 per share, with prices ranging from $48.215 to $49.08.
• All reported transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2025.
• After these transactions, Scott Dreyer beneficially owns 103,613 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction where an executive exercised options and sold shares under a pre-arranged 10b5-1 plan. This is a common occurrence and does not inherently signal a positive or negative outlook for the company, though it represents a profitable event for the executive.

Positives

• The executive realized a significant profit by exercising options at $15.9 per share and selling the shares at an average price of approximately $48 per share.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled and compliant approach to insider trading, which can mitigate concerns about opportunistic selling.

Negatives

• An executive selling shares, even under a 10b5-1 plan, reduces their direct equity stake in the company, which some investors might interpret as a slight negative, though it is a common practice for compensation realization.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction represents a routine executive compensation event and does not provide new fundamental information about the company's operations or strategy. The sale of shares by an executive, even under a 10b5-1 plan, could be viewed with slight caution by some investors, but the volume is not exceptionally large.
• Executive (Scott Dreyer): The executive realized a substantial personal gain from the profitable exercise of options and subsequent sale of shares.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving an executive exercising stock options and subsequently selling shares under a pre-established 10b5-1 trading plan. Such transactions are common and typically do not provide new fundamental information about the company's operational performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Collegium Pharmaceutical, COLL, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Executive Compensation, Scott Dreyer, Rule 10b5-1